Back to search
FDAFDA · Food and drugs·Recall number Z-1019-2017

OPT Croutons is a synthetic bone substitute designed for the repair of bony defects and is made of pure beta-tricalcium phosphate. The tricalcium phosphate is a soluble calcium phosphate salt.

Published January 18, 2017 · Recall initiated: December 5, 2016

Summary

FDA records medical device Class II recall Z-1019-2017, published January 18, 2017 and initiated December 5, 2016. Recalling firm: Acumed LLC; Status: Terminated; Reported quantity: 83 units distributed in the US; Lot: lot 549/12.001. Part number 65-0210-S. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

OPT Croutons, part number 65-0210-S, is recalled due to the result of inadequate documentation of the sterilization dose used in production. Product sterilized at the site did not receive the minimum dose required per the new performance qualification.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Acumed LLC
Distributor
distributed in FL, IN, KS, MI, MO, NE, OH, PA, TX and Peurto Rico.
Lot
lot 549/12.001. Part number 65-0210-S.
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was OPT Croutons is a synthetic bone substitute designed for the repair of bony defects and is made of pure beta-tricalcium phosphate. The tricalcium phosphate is a soluble calcium phosphate salt. recalled?

Yes. FDA published recall Z-1019-2017 on January 18, 2017. Reported hazard: OPT Croutons, part number 65-0210-S, is recalled due to the result of inadequate documentation of the sterilization dose used in production. Product sterilized at the site did not receive the minimum dose required per the new performance qualification.

What should I do if I have this product?

Voluntary: Firm initiated · Letter